Within the crowded skin booster
category, one class has captured a disproportionate share of clinical
attention: the polynucleotide. Often positioned as the most regenerative member
of the booster family, polynucleotides have moved from niche to near-essential
in the space of two years.
What they are
Polynucleotides are long-chain
fragments of DNA, most commonly purified from salmon or trout. Unlike classic
HA boosters, they do not primarily hydrate. They act as biological signals —
building blocks that prompt fibroblasts to increase collagen and elastin
production, while also exerting antioxidant activity that scavenges the free
radicals implicated in ageing. In short, they address the biology of the skin
rather than simply its water content.
Where they excel
Polynucleotides come into their
own precisely where hydrating boosters reach their limits. Practitioners
increasingly reach for them in cases of:
•
Genuinely
compromised skin quality — from sun damage, inflammatory conditions or advanced
ageing
•
Delicate,
crepey peri-ocular skin, where a regenerative rather than volumising approach
is needed
•
Fragile
or thinning skin that benefits from rebuilt extracellular matrix and improved
resilience
They are frequently described as
the best starting point for damaged, inflamed or scarred skin — the cases where
the tissue needs repair, not just moisture.
Protocol and expectations
Polynucleotides reward patience
and planning. A typical course runs to three sessions spaced two to four weeks
apart, with maintenance every six to nine months as the collagen-stimulating
effect is sustained. Results build progressively rather than instantly, and
clear expectation-setting is essential: this is a regenerative process, not an
immediate plumping effect.
Professional considerations
As with any injectable, source
and quality are decisive — purity of the DNA fraction and integrity of
manufacturing directly affect both safety and result. Counterfeit product is a
known risk in this fast-growing category, so verified supply matters. Regulatory
classification of polynucleotides also varies by market, and practitioners
should confirm local standing before adoption.